VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RXST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RXSTRxSight, Inc.
$4.54$188M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
RXST logo

RxSight, Inc.

RXST
NASDAQ · Eye & Dental Care
$4.54
At close - Nov 6, 4:00 PM EST - USD
Market Cap$188M
P/E-3.5x
52W High$13.22
Volume948.25K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Stall and Widening Losses Test RxSight's Turnaround

RxSight's reported revenue has stalled after its 2024 expansion, peaking at $45.4M in 2024Q3 and hovering between $24.6M and $33.7M since, with 2026Q3 down 19.0% year-over-year, while operating margin deteriorated to -75.3%.

GrowthContracting
ProfitabilityNegative
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

RXST price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

-113% Peers

P/E is 113% below peer median

03

Market leadership

RS 23 · Lag

Laggard (Underperforming 77% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 3

Market performance

Price History →

Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
RXST-56.26%
S&P 500 (^GSPC)+7.63%
1-Year Return
RXST-47.27%
S&P 500 (^GSPC)+9.69%
3-Year Return
RXST-81.15%
S&P 500 (^GSPC)+68.76%
5-Year Return
RXST-64.67%
S&P 500 (^GSPC)+56.80%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$134M-3.9% YoY
Net income FY25
-$39M-41.8% YoY
Free cash flow FY25
-$19M+13.6% YoY
Operating margin FY25
-35.8%-9.5 pts YoY
ROIC (FY25)-13.3%
Avg ROIC 5Y-22.4%
ROE (TTM)-20.1%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (75%)
Revenue Beat Rate7/12 (58%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
-$0.39-27.2%
vs -$0.31
$25M-9.6%
vs $27M
Q3 2026
Aug 5, 2026
-$0.29+12.0%
vs -$0.33
$34M+3.7%
vs $33M
Q2 2026
May 6, 2026
-$0.38-27.1%
vs -$0.30
$31M+3.8%
vs $30M
Q1 2026
Feb 25, 2026
-$0.22+34.3%
vs -$0.33
$33M+8.1%
vs $30M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Oct 23, 2026
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight's common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight's common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026.

GlobeNewsWire·Oct 20, 2026
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

ALISO VIEJO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the third quarter of 2026 after the market close on Tuesday, November 3, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire·Oct 19, 2026
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and Commercial Strategy.

GlobeNewsWire·Oct 16, 2026
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.

Filtered for RxSight, Inc.More Headlines
04

Compare before deciding

Benchmark RXST against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for RxSight, Inc. (RXST)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RXST logoRXSTRxSight, Inc.Current
$4.54$187.94M-3.55-3.89%-43.8%-20.11%—
LMAT logoLMATLeMaitre Vascular, Inc.
$80.89$1.85B29.4713.53%23.51%15.33%0.98%
ATRC logoATRCAtriCure, Inc.
$58.54$2.98B195.9814.88%2.52%2.93%—
IRTC logoIRTCiRhythm Technologies, Inc.
$90.22$2.96B-77.3926.24%-4.52%-22.8%—
TMDX logoTMDXTransMedics Group, Inc.
$88.24$3.05B24.9437.13%19.85%28.38%—
ALGN logoALGNAlign Technology, Inc.
$166.00$11.89B23.970.9%11.83%11.76%—

Compare RXST vs Peers

RxSight, Inc. (RXST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs LMAT

Most directly comparable listed peer for RXST.

Scale Benchmark

vs ABT

Larger-name benchmark to compare RXST against a more recognizable public peer.

Peer Set

Compare Top 5

vs LMAT, ATRC, IRTC, TMDX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

RXST SEC Filings & Documents

RxSight, Inc. (RXST) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Aug 5, 2026·SEC

Material company update

Jul 15, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 25, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 3, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when RXST posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RXST Frequently Asked Questions

RxSight, Inc. (RXST) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is RxSight, Inc.'s revenue?

RxSight, Inc. (RXST) reported $121.8M in revenue over the trailing twelve months. Revenue was $134.5M in fiscal year 2025. That is 5901% more than the $2.2M of fiscal year 2019.

How fast is RxSight, Inc. growing?

RxSight, Inc. (RXST) revenue fell by 14.3% over the trailing twelve months, compared with the twelve months before.

Is RXST profitable?

No. RxSight, Inc. (RXST) reported a net loss of $53.4M over the trailing twelve months.

Dividend & Returns
What is RXST's return on equity?

RxSight, Inc. (RXST) had a return on equity (ROE) of -20.1% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is RxSight, Inc.'s free cash flow?

RxSight, Inc. (RXST) generated $18.6M in free cash flow over the trailing twelve months.

What if you invested $1,000 in RXST back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →